KRAS and neoplasm: Indeed, no KRAS mutations were reported among Chinese patients with NSCLC with gCHEK2m. Furthermore, actionable driver alterations could only be detected in patients who are tumor ctDNA “shedders,” which is often a surrogate of tumor burden.